Busulfan, Fludarabine, and Cyclophosphamide (BFC) conditioning allowed stable engraftment after haplo-identical allogeneic stem cell transplantation in children with adrenoleukodystrophy and mucopolysaccharidosis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Optimization of T-cell-replete haploidentical hematopoietic stem cell transplantation: the Chinese experience.Haematologica · 2025
   Review
2. Semi-mechanistic population pharmacokinetic model incorporating glutathione S-transferase activity for personalized busulfan dosing in pediatric allogeneic hematopoietic cell transplantation.Frontiers in pharmacology · 2025
   Article
3. Current Concepts in the Management of Sanfilippo Syndrome (MPS III): A Narrative Review.Cureus · 2024
   Review
4. Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022
   Review
5. External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients.Frontiers in pharmacology · 2022
   Article
6. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.Journal of hematology & oncology · 2021
   Article
7. A Cure for Sanfilippo Syndrome? A Summary of Current Therapeutic Approaches and their Promise.Medical research archives · 2020
   Article
8. Considerations in Preparative Regimen Selection to Minimize Rejection in Pediatric Hematopoietic Transplantation in Non-Malignant Diseases.Frontiers in immunology · 2020
   Review
9. Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.Bone marrow transplantation · 2019
   Review
10. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments.Drugs · 2019
    Review
11. Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Review
12. [Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019
    Article
13. Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation.Frontiers in immunology · 2019
    Review
14. [Advances in haploidentical hematopoietic stem cell transplantation for non-malignant hematological diseases].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2018
    Article
15. First bone marrow transplantation for mucopolysaccharidosis type I in Vietnam: a case report.Therapeutic advances in rare disease
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as